Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547908 | 0.86 | CLK2 (0.37) | CXCR4HRH3MAPTALDH1A1 | |
| SCHEMBL10039360 | 0.84 | CLK2 (0.41) | HRH3MAPTHSD17B10ALDH1A1 | |
| SCHEMBL4553878 | 0.80 | CXCR4 (0.53) | CXCR4SMN1; SMN2HRH3ALOX15CYP2A13 | |
| SCHEMBL12028978 | 0.79 | CXCR4 (0.71) | CXCR4SMN1; SMN2HRH3MAPTALOX15 | |
| SCHEMBL11960352 | 0.77 | HRH3 (0.53) | CXCR4SMN1; SMN2HRH3MAPTALOX15 | |
| SCHEMBL15260256 | 0.76 | CXCR4 (0.53) | CXCR4SMN1; SMN2HRH3ALOX15CYP2A13 | |
| SCHEMBL20937776 | 0.75 | CXCR4 (0.47) | CXCR4SMN1; SMN2HRH3MAPTALOX15 | |
| SCHEMBL179331 | 0.73 | KMT2A (0.42) | SMN1; SMN2MAPTHSD17B10MEN1ALDH1A1 | |
| SCHEMBL11960346 | 0.73 | MAPT (0.46) | CXCR4SMN1; SMN2HRH3MAPTALOX15 | |
| SCHEMBL14905955 | 0.72 | CXCR4 (0.47) | CXCR4SMN1; SMN2HRH3MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011116176-A1 | 3-SUBSTITUED IMIDAZO (4, 5-B) PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CXCR4 3452/4885SMN1; SMN2 2271/4885HRH3 3555/4885 |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | CXCR4 3575/4885SMN1; SMN2 3331/4885HRH3 3415/4885 |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | CXCR4 4720/4885SMN1; SMN2 2090/4885HRH3 3639/4885 |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CXCR4 3796/4885SMN1; SMN2 2153/4885HRH3 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.